3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$80M | 0.0% | -1502.4% | -$30M | — | $110M |
| 2024 | $652000 | -$52M | 0.0% | -8142.3% | -$46M | — | $64M |
| 2023 | $350000 | -$49M | 0.0% | -14822.6% | -$45M | — | $38M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$18M | 0.0% | -1010.1% | -$11M | — | $99M |
| Dec '25 | — | -$40M | — | — | $6M | — | $110M |
| Sep '25 | — | -$15M | — | — | -$11M | — | $75M |
| Jun '25 | — | -$13M | — | — | -$10M | — | $39M |
| Mar '25 | $858000 | -$12M | 0.0% | -1526.8% | -$15M | — | $49M |
| Dec '24 | — | -$13M | — | — | -$12M | — | $64M |
| Sep '24 | — | -$13M | — | — | -$10M | — | $3M |
| Jun '24 | — | -$13M | — | — | -$14M | — | — |
| Mar '24 | — | -$12M | — | — | -$11M | — | — |
| Dec '23 | $0 | -$13M | — | — | -$12M | — | $38M |
| Sep '23 | $350000 | -$12M | 0.0% | -3525.1% | — | — | $50M |
| Jun '23 | — | -$12M | — | — | — | — | — |
| Mar '23 | — | -$13M | — | — | — | — | — |
How the market has priced CAMP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Camp4 Therapeutics Corp's revenue has grown 216.1% per year. These are computed facts, not advice.
As of FY2025, Camp4 Therapeutics Corp reported — of total debt against $110M of cash.
In FY2025, gross margin was —, operating margin -1502.4%, and net margin -2298.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.